Date Title Description PDF
03 Nov 2021 On buy-back programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Download
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download
22 Jun 2021 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Download
22 Jun 2021 On significant placements in financial instruments Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. Download
29 Apr 2021 On business and financial situation The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.     Download

Pages

Date Title Description PDF
24 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 17 November and 23 November 2023 Download
17 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 10 November and 16 November 2023 Download
10 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 3 November and 9 November 2023 Download
03 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 27 October and 2 November 2023 Download
27 Oct 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 20 October and 26 October 2023 Download

Pages

Date Title Description PDF
06 Apr 2017 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the first quarter of 2017 Download
13 Mar 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to its biosimilar of Enoxaparin Download
07 Mar 2017 Otros sobre negocio y situación financiera ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome Download
16 Feb 2017 Otros sobre Gobierno Corporativo The Company informs about the agreements adopted by the Board of Directors Download
16 Feb 2017 Informe anual de remuneraciones de los consejeros ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors Download

Pages